Context: Urinary bladder diagnosis can be challenging and conventional markers used were cytokeratins. The new additions are GATA 3, uroplakin and S100P. This study helps to analyze immunohistochemical expression of panel of markers across the spectrum of urinary bladder tumors.

Aims: 1. to evaluate immunohistochemical expression in various subtypes of urothelial neoplasms of the urinary bladder and to correlate this expression with the grade of the tumor. 2. To distinguish between reactive urothelium and carcinoma in situ/ dysplasia using immunoprofile work up.

Settings and Design: Study was performed in the department of Pathology in RGCIRC, Delhi with 70 cases of urinary bladder lesions during period of one year.
Methods and Material: longitudinal study
Statistical Analysis: The tissue sections were scored using CK, UROPLAKIN II, GATA 3, S100P, CD44, p16 and KI 67

Results: 1. CK7+ and CK20+in 92% and 77% cases. p16+ in 83% and CD 44+ in 84%. Newer markers: Uroplakin II-75%; S100P-82% and GATA3-96%positivity. CD44+ in reactive urothelium 5/5 and CK20+ in CIS (12/12) cases. p16+ in 4/5 cases of reactive atypia and CIS 12/12 cases.

Conclusions: The markers are sensitive for urothelial origin & have to be used as panel wherever required.

Keywords: Uroplakin II; Gata 3; Bladder Carcinoma